Calcium Supplements in Patients With Cardiovascular Disease: Time for a More Cautious Approach?

Calcium supplementation has long been a cornerstone of osteoporosis prevention, particularly in older adults. However, emerging data raise important questions about its cardiovascular safety—especially in patients with established cardiovascular disease (CVD).

New Evidence in Patients With Established CVD

A large population-based cohort study from Hong Kong evaluated more than 230,000 adults aged 40 and older newly diagnosed with CVD. After propensity matching, calcium supplementation was associated with a higher risk of recurrent cardiovascular events, including myocardial infarction and stroke. The risk was more pronounced in:

• Patients taking calcium alone (without vitamin D)
• Men
• Those receiving higher daily doses (≥ 1,000 mg)

Importantly, patients taking calcium combined with vitamin D did not show an increased risk of recurrent events in this study, suggesting that co-supplementation may modify risk.

These findings extend prior concerns—largely derived from general populations—to patients with known CVD, a group already at high baseline risk.

Why Might Calcium Supplements Increase Risk?

Unlike dietary calcium, which is absorbed gradually, calcium supplements can produce transient increases in serum calcium levels. Repeated post-supplement “calcium spikes” may:

• Promote vascular calcification
• Increase arterial stiffness
• Enhance coagulability

Mendelian randomization studies and prior meta-analyses have also linked higher circulating calcium levels to increased risk of myocardial infarction, supporting a biologically plausible mechanism.

What About Vitamin D?

Vitamin D deficiency is associated observationally with adverse cardiovascular outcomes. However, randomized trials have generally failed to show cardiovascular benefit from vitamin D supplementation alone. Current evidence does not support vitamin D for primary cardiovascular prevention, although its role when combined with calcium remains debated.

Dietary vs Supplemental Calcium

One consistent theme across studies is the difference between dietary calcium and supplemental calcium. Dietary calcium intake has not been consistently associated with increased cardiovascular risk and may even be protective in some cohorts. In contrast, several meta-analyses of randomized trials have reported a modest increase in myocardial infarction risk with calcium supplements, particularly when not combined with vitamin D.

Guideline Perspective

The 2023 AHA/ACC guideline for chronic coronary disease recommends against the use of nonprescription supplements—including calcium—for reducing cardiovascular events. Calcium should not be used with the expectation of cardiovascular benefit.

Practical Takeaways for Clinicians

• In patients with established CVD, routine calcium supplementation should be reconsidered, particularly calcium-only therapy.
• When supplementation is necessary for bone health, consider:
  • Using the lowest dose needed to meet recommended intake
  • Preferring dietary calcium sources
  • Avoiding high-dose calcium-only regimens
• Management decisions should balance fracture risk against potential cardiovascular risk.

As with many areas in preventive cardiology, “more is not necessarily better.” For patients with cardiovascular disease, a thoughtful, individualized approach to calcium supplementation is warranted.

---

References

1. Zhang X, et al. Association between calcium supplementation and recurrence of cardiovascular events in patients with cardiovascular disease. J Am Heart Assoc. 2026;15:e047455.
2. Bolland MJ, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691.
3. Chung M, et al. Vitamin D and calcium supplementation in prevention of cardiovascular events: systematic review. Ann Intern Med. 2010;152:315–323.
4. ACC/AHA Joint Committee on Clinical Practice Guidelines. 2023 Guideline for the Management of Patients With Chronic Coronary Disease. Circulation. 2023.